Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

Cassandra Calabrese

doi:10.1016/j.rdc.2022.02.001

Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy

Rheum Dis Clin North Am. 2022 May;48(2):397-409. doi: 10.1016/j.rdc.2022.02.001.

Author

Cassandra Calabrese¹

Affiliation

¹ Department of Rheumatologic & Immunologic Disease, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A50, Cleveland, OH 44195, USA. Electronic address: calabrc@ccf.org.

PMID: 35400367
DOI: 10.1016/j.rdc.2022.02.001

Abstract

Patients with rheumatic diseases are susceptible to infections due to their underlying disease states as well as from immunosuppressive medications, highlighting the importance of vaccination, these same factors also pose challenges to vaccine efficacy, safety, and uptake. This article reviews the impact of immunosuppressive therapies and rheumatic disease on vaccine efficacy in this vulnerable patient population as well as discusses best practices.

Keywords: Biologics; DMARD; Immunogenicity; Immunosuppression; Infection; Rheumatic diseases; Vaccine.

Publication types

Review

MeSH terms

Antirheumatic Agents* / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Rheumatic Diseases* / drug therapy
Vaccination

Substances

Antirheumatic Agents
Immunosuppressive Agents